A Phase 2/3 interventional study of Timolol Maleate Gel+Placebo and Timolol Maleate Gel in Infantile Hemangioma, sponsored by Auson Pharmaceuticals Inc.. Completed at 8 sites in China. Open to participants aged 35 Days to 150 Days. Per ClinicalTrials.gov, last updated 2024-11-07.
Sponsored by Auson Pharmaceuticals Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hemangioma, Capillary with a site in China — 6 open to participants now, 7 under way, 1 of them phase 3. Hemangioma, Capillary · China.
Among the 12 studies in Hemangioma, Capillary with a site in China, this one is the only one that started in 2020, is one of 2 in phase 2/3, and was the 5th registered.
35 studies on the registry are indexed under Hemangioma, Capillary; 6 are open to participants now.
Browse Hemangioma, Capillary studies →6 of the 12 studies in Hemangioma, Capillary with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 0 days–7 days · Healthy volunteers
West China Hospital · Sites in China
Ages 0 mo–12 mo
West China Hospital · Sites in China
Ages up to 6
West China Hospital · Sites in China
Ages 6 mo–60 mo
West China Hospital · Sites in China
Ages 0 mo–12 mo
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 3 Hemangioma, Capillary studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 35 Days to 150 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 1
First in 2013; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 168 is above the median of 78 across 20 interventional studies indexed under Hemangioma, Capillary.
Median enrollment 168 across the 5 interventional studies, 150 across the 7 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 5 most frequent:
Auson Pharmaceuticals Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Auson Pharmaceuticals Inc. has 1 study filed under Hemangioma, Capillary — fewer than ten, so there is no comparison to draw.
3 of the studies in Hemangioma, Capillary with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938710West China HospitalIncidence and Clinical Features of PHACE Syndrome | 2027-03-31 |
| NCT07616323West China HospitalScreening LUMBAR Syndrome in Infants With Infantile Hemangiomas | 2027-06-30 |
| NCT07938723West China HospitalThe Incidence and Clinical Characteristics of Infantile Hemangiomas | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies in Hemangioma, Capillary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the safety and efficacy of timolol maleate (TM) gel in subjects with superficial infantile hemangioma (IH) in the proliferative phase. The main question it aims to answer is:
Researchers will compare TM gel to a placebo (a look-alike substance that contains no drug) to see if TM gel works to treat IH.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
56 patients will be randomized to group 1.
Drug: Timolol Maleate Gel+Placebo
56 patients will be randomized to group 2.
Drug: Timolol Maleate Gel
56 patients will be randomized to group 3.
Drug: Placebo
Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.
Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.
Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.
Success rate of cure of IH after 24-week treatment.
Treatment success is defined as complete or almost complete resolution of the patient's IH at W24 compared with baseline. At the time of centralized independent assessment.
Time frame: 24 weeks
Changes in the hemangioma volume
Changes in the hemangioma volume from baseline after treatment for 4, 12 and 24 weeks, adopting the estimation formula of IH volume: V = 0.07×(the average of the hemangioma's longest length and width)\^3.
Time frame: baseline, week 4, 12 and 24
Changes in hemangioma color
Change in the color of hemangioma after 4, 12, and 24 weeks of treatment, which is assessed by the CEA (Clinician Erythema Assessment) criteria.The color intensity (e.g., no signs of erythema;slight redness;defined redness;marked redness;fiery redness.) of the IH is assessed on a 5 point scale.
Time frame: baseline, weeks 4, 12 and 24
Complete/almost complete regression rates of IH from baseline after 4 and 12-week treatment.
At the time of centralized independent assessment.
Time frame: baseline, weeks 4 and 12
Complete/almost complete resolution rate of IH at each post-baseline visit (Weeks 4, 12, and 24) from baseline.
On-site qualitative assessment by the investigator of efficacy.
Time frame: baseline, Weeks 4, 12, and 24
Evolution of IH at each post-baseline visit(Weeks 4, 12, and 24) from baseline.
Classified into 5 categories: completely/almost completely resolved, improved, stable, aggravated, and not assessable. On-site qualitative assessment by the investigator of efficacy.
Time frame: baseline, Weeks 4, 12 and 24
Changes in IH at each post-baseline visit(Weeks 4, 12, and 24) compared to the previous visit.
Classified into 5 categories: complete/almost complete regression, relief, stabilization, exacerbation, and unable to determine. On-site qualitative assessment by the investigator of efficacy.
Time frame: Baseline, Weeks 4, 12, and 24
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2020 to primary completion in Jun 2022, 19 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Timolol
Auson Pharmaceuticals Inc.